Alexander Sherman, MD
Pulmonary Disease · Los Angeles, CANPI 1760864367
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Tanabe Pharma America, Inc. at 42.0% of the total. 2024 is the largest year on record at $3,129, 9.4 times the $333 reported in 2019.
Across 106 payments — averaging $60.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$3K
- Actelion Pharmaceuticals US, Inc.$2K
- Bayer$677
- United Therapeutics Corporation$397
- Inari Medical, Inc.$391
- La Jolla Pharmaceutical Company$150
- plus $414 from 4 others
Across 2 payments — averaging $399,189 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amylyx Pharmaceuticals, Inc.$500K
- Biogen$298K
What the payments were for
- Consulting fees$2,66041%
- Food & beverage$3,71458%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 2 | $2,710 |
| Actelion Pharmaceuticals US, Inc. | 60 | $1,716 |
| Bayer | 22 | $677 |
| United Therapeutics Corporation | 15 | $397 |
| Inari Medical, Inc. | 2 | $391 |
| La Jolla Pharmaceutical Company | 1 | $150 |
| Genentech USA, Inc. | 1 | $147 |
| Penumbra, Inc. | 1 | $130 |
| Pfizer | 1 | $70 |
| Biogen | 1 | $67 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Radicava$2,660
- Radicava ORS$2,660
- UPTRAVI$386
- FLOWTRIEVER CATHETER, S$356
- CT THROMBECTOMY SYSTEM KIT$356
- OPSUMIT$236
- GIAPREZA$150
- Esbriet$147
- Indigo System$130
How this compares
$6,454 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 45 | $568,339 |
| UptraviSelexipag | 13 | $299,767 |
| Tyvaso Refill KitTreprostinil/Neb Accessories | 11 | $226,724 |
| AdempasRiociguat | 16 | $226,181 |
| LetairisAmbrisentan | 14 | $166,850 |
| Ambrisentan | 28 | $61,863 |
| Tadalafil | 65 | $56,259 |
| EliquisApixaban | 24 | $33,540 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $11,064 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,122 |
| Potassium Chloride | 12 | $492 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $319 |
| Furosemide | 22 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,716 | $868,10658 claims |
| BayerAdempas | $677 | $226,18116 claims |
| PfizerEliquis | $70 | $33,54024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.